[HTML][HTML] Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance
HS Khalil, V Mitev, T Vlaykova, L Cavicchi… - Journal of …, 2015 - Elsevier
Seliciclib (R-Roscovitine) was identified as an inhibitor of CDKs and has undergone drug
development and clinical testing as an anticancer agent. In this review, the authors describe …
development and clinical testing as an anticancer agent. In this review, the authors describe …
Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance.
HS Khalil, V Mitev, T Vlaykova, L Cavicchi… - Journal of …, 2015 - europepmc.org
Seliciclib (R-Roscovitine) was identified as an inhibitor of CDKs and has undergone drug
development and clinical testing as an anticancer agent. In this review, the authors describe …
development and clinical testing as an anticancer agent. In this review, the authors describe …
[PDF][PDF] Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance
HS Khalil, V Mitev, T Vlaykova, L Cavicchi… - Journal of …, 2015 - cyberleninka.org
abstract Seliciclib (R-Roscovitine) was identified as an inhibitor of CDKs and has undergone
drug development and clinical testing as an anticancer agent. In this review, the authors …
drug development and clinical testing as an anticancer agent. In this review, the authors …
Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance
HS Khalil, V Mitev, T Vlaykova, L Cavicchi… - Journal of …, 2015 - infona.pl
Seliciclib (R-Roscovitine) was identified as an inhibitor of CDKs and has undergone drug
development and clinical testing as an anticancer agent. In this review, the authors describe …
development and clinical testing as an anticancer agent. In this review, the authors describe …
[引用][C] Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance
HS Khalil, V Mitev, T Vlaykova, L Cavicchi… - Journal of …, 2015 - cir.nii.ac.jp
Discovery and development of Seliciclib. How systems biology approaches can lead to better
drug performance | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …
drug performance | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …
[PDF][PDF] Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance
HS Khalil, V Mitev, T Vlaykova, L Cavicchi, N Zhelev - 2015 - researchgate.net
abstract Seliciclib (R-Roscovitine) was identified as an inhibitor of CDKs and has undergone
drug development and clinical testing as an anticancer agent. In this review, the authors …
drug development and clinical testing as an anticancer agent. In this review, the authors …
Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance
HS Khalil, V Mitev, T Vlaykova, L Cavicchi… - Journal of …, 2015 - rke.abertay.ac.uk
Seliciclib (R-Roscovitine) was identified as an inhibitor of CDKs and has undergone drug
development and clinical testing as an anticancer agent. In this review, the authors describe …
development and clinical testing as an anticancer agent. In this review, the authors describe …
Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance
HS Khalil, V Mitev, T Vlaykova… - Journal of …, 2015 - pubmed.ncbi.nlm.nih.gov
Seliciclib (R-Roscovitine) was identified as an inhibitor of CDKs and has undergone drug
development and clinical testing as an anticancer agent. In this review, the authors describe …
development and clinical testing as an anticancer agent. In this review, the authors describe …
[PDF][PDF] Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance
HS Khalil, V Mitev, T Vlaykova, L Cavicchi… - Journal of …, 2015 - academia.edu
abstract Seliciclib (R-Roscovitine) was identified as an inhibitor of CDKs and has undergone
drug development and clinical testing as an anticancer agent. In this review, the authors …
drug development and clinical testing as an anticancer agent. In this review, the authors …
Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance
HS Khalil, V Mitev, T Vlaykova… - Journal of …, 2015 - discovery.dundee.ac.uk
Seliciclib (R-Roscovitine) was identified as an inhibitor of CDKs and has undergone drug
development and clinical testing as an anticancer agent. In this review, the authors describe …
development and clinical testing as an anticancer agent. In this review, the authors describe …